Role and expression of FRS2 and FRS3 in prostate cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Valencia, Tania ^a   Joseph, Ajay ^a   Kachroo, Naveen ^a   Darby, Steve ^b   Meakin, Susan ^c   Gnanapragasam, Vincent J ^a  

^a HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Adaptor proteins; Fgf signalling; Frs2; Frs3; Prostate cancer

Indexed keywords

ADAPTOR PROTEIN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR RECEPTOR SUBSTRATE 2; FIBROBLAST GROWTH FACTOR RECEPTOR SUBSTRATE 3; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; FRS2 PROTEIN, HUMAN; FRS3 PROTEIN, HUMAN; MEMBRANE PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR PROTEIN;

ARTICLE; CANCER CELL; CANCER GRADING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME SUBSTRATE; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IRRADIATION; MALE; PATHOPHYSIOLOGY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR BIOPSY; CELL MOTION; COHORT ANALYSIS; GENETICS; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; RADIATION EXPOSURE; TUMOR CELL LINE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; COHORT STUDIES; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS;

EID: 81055149761     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-484     Document Type: Article

References (40)

1. Turner N, Grose R. Fibroblast Growth Factors. From development to cancer. Nat Rev Cancer 2010, 10:116-129. 10.1038/nrc2780, 20094046.
2. Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010, 125:105-117. 10.1016/j.pharmthera.2009.10.001, 19874848.
3. Murphy T, Hori S, Sewell J, Gnanapragasam VJ. Expression and functional role of negative signalling regulators in tumour development and progression. Int J Cancer 2010, 127:2491-2499. 10.1002/ijc.25542, 20607827.
4. Gnanapragasam VJ, Robinson MC, Marsh C, Robson CN, Hamdy FC, Leung HY. FGF8 isoform b expression in human prostate cancer. Br J Cancer 2003, 88:1432-1438. 10.1038/sj.bjc.6600875, 2741033, 12778074.
5. Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 2007, 213:82-90. 10.1002/path.2205, 17607666.
6. Murphy T, Darby S, Mathers ME, Gnanapragasam VJ. Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J Pathol 2010, 220:452-460.
7. Feng S, Wang F, Matsubara A, Kan M, McKeehan WL. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Research 1997, 57:5369-5378.
8. Freeman KW, Gangula RD, Welm BE, Ozen M, Foster BA, Rosen JM, Ittmann M, Greenberg NM, Spencer DM. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal regulated kinase activation, and in vivo proliferation. Cancer Res 2003, 63:6237-6243.
9. Xu H, Lee KW, Goldfarb M. Novel recognition motif on fibroblast growth factor receptor mediates direct association and activation of SNT adapter proteins. J Biol Chem 1998, 273:17987-17990. 10.1074/jbc.273.29.17987, 9660748.
10. Zhou W, Feng X, Wu Y, Benge J, Zhang Z, Chen Z. FGF-receptor substrate 2 functions as a molecular sensor integrating external regulatory signals into the FGF pathway. Cell Res 2009, 19:1165-11677. 10.1038/cr.2009.95, 19652666.
11. Stoletov KV, Ratcliffe KE, Terman BI. Fibroblast growth factor receptor substrate 2 participates in vascular endothelial growth factor-induced signalling. Faseb J 2002, 16:1283-1285.
12. Melillo RM, Santoro M, Ong SH, Billaud M, Fusco A, Hadari YR, Schlessinger J, Lax I. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signalling cascade. Mol Cell Biol 2001, 21:4177-4187. 10.1128/MCB.21.13.4177-4187.2001, 87079, 11390647.
13. Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, Schlessinger J. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signalling pathway. Cell 1997, 89:693-702. 10.1016/S0092-8674(00)80252-4, 9182757.
14. Meakin SO, MacDonald JI, Gryz EA, Kubu CJ, Verdi JM. The signalling adapter FRS-2 competes with Shc for binding to the nerve growth factor receptor TrkA. A model for discriminating proliferation and differentiation. J Biol Chem 1999, 274:9861-9870. 10.1074/jbc.274.14.9861, 10092678.
15. Dixon SJ, MacDonald JI, Robinson KN, Kubu CJ, Meakin SO. Trk receptor binding and neurotrophin/fibroblast growth factor (FGF)-dependent activation of the FGF receptor substrate (FRS)-3. Biochim Biophys Acta 2006, 1763:366-380. 10.1016/j.bbamcr.2006.02.009, 16697063.
16. Gotoh N, Manova K, Tanaka S, Murohashi M, Hadari Y, Lee A, Hamada Y, Hiroe T, Ito M, Kurihara T, Nakazato H, Shibuya M, Lax I, Lacy E, Schlessinger J. The docking protein FRS2alpha is an essential component of multiple fibroblast growth factor responses during early mouse development. Mol Cel Biol 2005, 25:4105-4116.
17. Hadari YR, Gotoh N, Kouhara H, Lax I, Schlessinger J. Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. Proc Natl Acad Sci USA 2001, 98:8578-8583. 10.1073/pnas.161259898, 37478, 11447289.
18. Gotoh N, Laks S, Nakashima M, Lax I, Schlessinger J. FRS2 family docking proteins with overlapping roles in activation of MAP kinase have distinct spatial-temporal patterns of expression of their transcripts. FEBS Lett 2004, 564:14-18. 10.1016/S0014-5793(04)00287-X, 15094036.
19. Iejima D, Minegishi Y, Takenaka K, Siswanto A, Watanabe M, Huang L, Watanabe T, Tanaka F, Kuroda M, Gotoh N. FRS2β, a potential prognostic gene for non-small cell lung cancer, encodes a feedback inhibitor of EGF receptor family members by ERK binding. Oncogene 2010, 29:3087-3099. 10.1038/onc.2010.69, 20228838.
20. Huang L, Watanabe M, Chikamori M, Kido Y, Yamamoto T, Shibuya M, Gotoh N, Tsuchida N. Unique role of SNT-2/FRS2beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signalling pathways. Oncogene 2006, 25:6457-6466. 10.1038/sj.onc.1209656, 16702953.
21. Hryciw T, MacDonald JI, Phillips R, Seah C, Pasternak S, Meakin SO. The fibroblast growth factor receptor substrate 3 adapter is a developmentally regulated microtubule-associated protein expressed in migrating and differentiated neurons. J Neurochem 2010, 112:924-939. 10.1111/j.1471-4159.2009.06503.x, 19943849.
22. Ranzi V, Meakin SO, Miranda C, Mondellini P, Pierotti MA, Greco A. The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins. Endocrinology 2003, 144:922-928. 10.1210/en.2002-221002, 12586769.
23. Carter S, Auer KL, Reardon DB, Birrer M, Fisher PB, Valerie K, Scmidtt-Ullrich R, Mikkelsen R, Dent P. Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene 1998, 16:2787-2796. 10.1038/sj.onc.1201802, 9652746.
24. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich R. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999, 10:2493-2506. 25480, 10436007.
25. Joseph A, Gnanapragasam VJ. Laser Capture microdissection and transcriptional profiling in archival FFPE tissue in prostate cancer. Meth Mol Biol 2011, 755:291-300.
26. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22. 10.1016/j.ccr.2010.05.026, 3198787, 20579941.
27. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004, 11:709-724. 10.1677/erc.1.00535, 15613447.
28. Valve EM, Nevalainen MT, Nurmi MJ, Laato MK, Martikainen PM, Härkönen PL. Increased expression of FGF-8 isoforms and FGF receptors in human pre malignant prostatic intraepithelial neoplasia lesions and prostate cancer. Lab Invest 2001, 81:815-826.
29. Heer R, Douglas D, Mathers ME, Robson CN, Leung HY. Fibroblast growth factor 17 is over-expressed in human prostate cancer. J Pathol 2004, 204:578-586. 10.1002/path.1668, 15538740.
30. Li ZG, Mathew P, Yang J, Michael W, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin S-H, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 2008, 118:2697-2710. 2447924, 18618013.
31. Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 1999, 18:2755-2761. 10.1038/sj.onc.1202624, 10348350.
32. Naimi B, Latil A, Fournier G, Mangin P, Cussenot O, Berthon P. Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate 2002, 52:245-252. 10.1002/pros.10104, 12111699.
33. Ropiquet F, Huguenin S, Villette JM, Ronflé V, Le Brun G, Maitland NJ, Cussenot O, Fiet J, Berthon P. FGF7/KGF triggers cell transformation and invasion on immortalised human prostatic epithelial PNT1A cells. Int J Cancer 1999, 82:237-243. 10.1002/(SICI)1097-0215(19990719)82:2<237::AID-IJC14>3.0.CO;2-Q, 10389758.
34. Wang F. Cell- and receptor isotype-specific phosphorylation of SNT1 by fibroblast growth factor receptor tyrosine kinases. In Vitro Cell Dev Biol Anim 2002, 38:178-183. 10.1290/1071-2690(2002)038<0178:CARISP>2.0.CO;2, 12026167.
35. Ozen M, Giri D, Ropiquet F, Mansukhani A, Ittmann M. Role of fibroblast growth factor receptor signalling in prostate cancer cell survival. J Natl Cancer Inst 2001, 93:1783-1790. 10.1093/jnci/93.23.1783, 11734594.
36. Yacoub A, Park JS, Qiao L, Dent P, Hagan MP. MAPK dependence of DNA damage repair: ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2 dependent fashion. Int J Radiat Biol 2001, 77:1067-1078. 10.1080/09553000110069317, 11682011.
37. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signalling. Radiat Res 2003, 159:439-452. 10.1667/0033-7587(2003)159[0439:EGFAIR]2.0.CO;2, 12643788.
38. Reardon DB, Contessa JN, Mikkelsen RB, Valerie K, Amir C, Dent P, Schmidt-Ullrich RK. Dominant negative EGFR-CD533 and inhibition of MAPK activity modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene 1999, 18:4756-4766. 10.1038/sj.onc.1202849, 10467423.
39. Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2003, 2:1113-1120.
40. Quick QA, Gewirtz DA. Enhancement of radiation sensitivity, delay of proliferative recovery after radiation and abrogation of MAPK (p44/42) signalling by imatinib in glioblastoma cells. Int J Oncol 2006, 29:407-412.